Evaluating work activity and societal burden in patients with grade 2 IDH-mutant glioma
Neuro-Oncology Practice · 01.04.2026 · 13 (2) · 331-341
DOI: 10.1093/nop/npaf092 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology Practice, online erschienen am 01.09.2025. Verfasst von Slávka Lukacova und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Servier International.
Abstract (Originalsprache)
Background
IDH-mutant (mIDH) gliomas affect relatively young and otherwise healthy patients with high workforce participation. Management typically involves surgery, radiotherapy, and/or chemotherapy (RT/CT), although immediate post-surgery treatment may be deferred in favor of active observation (AO) to preserve functioning. This study aimed to evaluate how disease progression and treatments impact work activity, medical and societal costs, and overall survival (OS) in grade 2 mIDH glioma patients initially managed with AO.
Methods
This retrospective longitudinal study utilized Danish administrative registries. Patients with mIDH gliomas initially managed with AO between 2010 and 2022 were included. Employment rates, sick leaves, treatment patterns, medical resources and costs, and OS were examined from diagnosis to the end of follow-up or death.
Results
Data from 237 patients were analyzed; 72.9% were alive at 10 years. After surgical recovery, ability to work was most impaired during RT/CT, necessitating nearly full-time sick leave. Work activity continuously decreased after each RT/CT treatment. Employment rates were similarly affected, from under 20% unemployment at baseline and during AO, up to 41% and 59% after first and second RT/CT. Similar trends were observed for medical resources and costs, and productivity losses.
Conclusions
Patients with grade 2 mIDH glioma remain active at work after initial surgery when managed with AO. Work impairment increases over successive RT/CT courses, highlighting the need to preserve quality of life by integrating work ability into clinical practice and by developing new treatment strategies to delay aggressive therapies and avoid substantial medical and productivity costs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
- Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.
- Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
- Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden.
- Quantify Research, Stockholm, Sweden.
- Servier International, Suresnes, France.
ORCID-Profile: Slávka Lukacova, Aida Muhic, Oskar Ström, Morten Johnsen, Céline Aubin, Marc Massetti, Jane Skjøth-Rasmussen
Förderung
- Servier International
Zitieren
APA
Lukacova, S., Muhic, A., Ström, O., Johnsen, M., Aubin, C., Massetti, M., & Skjøth-Rasmussen, J. (2026). Evaluating work activity and societal burden in patients with grade 2 IDH-mutant glioma. Neuro-Oncology Practice, 13(2), 331-341. https://doi.org/10.1093/nop/npaf092
Vancouver
Lukacova S, Muhic A, Ström O, Johnsen M, Aubin C, Massetti M, et al. Evaluating work activity and societal burden in patients with grade 2 IDH-mutant glioma. Neuro-Oncology Practice. 2026;13(2):331-341. doi:10.1093/nop/npaf092
BibTeX
@article{Lukacova2026,
author = {Lukacova, Slávka and Muhic, Aida and Ström, Oskar and Johnsen, Morten and Aubin, Céline and Massetti, Marc and Skjøth-Rasmussen, Jane},
title = {Evaluating work activity and societal burden in patients with grade 2 IDH-mutant glioma},
journal = {Neuro-Oncology Practice},
year = {2026},
volume = {13},
number = {2},
pages = {331--341},
doi = {10.1093/nop/npaf092}
}
EUVIMED